ITM Isotope Technologies Munich
ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).
Overview
ITM Isotope Technologies Munich is the largest supplier of non-carrier-added lutetium-177, sold as EndolucinBeta, and the developer of ITM-11, or 177Lu-edotreotide. ITM-11 was positive in the COMPETE phase 3 trial in gastroenteropancreatic neuroendocrine tumours in 2025, and the company is investing in actinium-225 supply. Nuclide links it to neuroendocrine tumours, to somatostatin receptor 2 as a target, to peptide receptor radionuclide therapy and the therapeutic isotope supply chain, to the radiopharmaceutical roadmap, and to the idea of building Western ytterbium-176 enrichment so lutetium-177 has more than one supplier. Manufacturing cost and time for radioactive medicines is the bottleneck it sits inside. Whether a supplier can also succeed as a drug developer is the open question.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
- 24-month regulatory events +4
- registry trials +8
Manufacturing
Capacity map- ITM Garching Garching, DERadioisotope production, Radiopharmaceutical manufacturing
A second lutetium radioligand for neuroendocrine tumours that beat the standard pill everolimus in a head-to-head trial and is awaiting an FDA decision.
Similar pages
not linked directly; found by shared links- CompanyOrano Med
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Manufacturing cost and time for living and radioactive medicines, Actinium-225 supply: thorium stocks, accelerators and radium targets, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanyTerraPower Isotopes
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Manufacturing cost and time for living and radioactive medicines, Actinium-225 supply: thorium stocks, accelerators and radium targets, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanyRayzeBio (BMS)
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- AgentActinium-225 DOTATATE
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Actinium-225 supply: thorium stocks, accelerators and radium targets, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares 177Lu-edotreotide, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
- CompanyEckert & Ziegler
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Actinium-225.
- CompanyNiowave
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Actinium-225.
- TrialCOMPETE
Shares 177Lu-edotreotide, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.